NY-SK-CAPITAL-PARTNERS
6.4.2021 07:32:06 CEST | Business Wire | Press release
SK Capital Partners, LP, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, has completed its previously announced acquisition of IPACKCHEM Group SAS (“IPACKCHEM” or the “Company”), a leader in sustainability-oriented barrier packaging.
Founded in 1987 by Jean-Philippe Morvan as a division of Air Products Group, IPACKCHEM is a leading global supplier of innovative and specialized barrier packaging solutions. IPACKCHEM’s leading market positions in the Crop Protection and Specialty Chemical markets are further underscored by its commitment to providing 100% recyclable plastic barrier packaging. IPACKCHEM is headquartered in Paris, with global operations spanning seven countries and four continents.
IPACKCHEM represents SK’s second investment in the packaging sector. Stephen D’Incelli, Managing Director at SK Capital, stated, "The transaction is a testament to SK’s ability to leverage our global platform to identify leading materials technologies businesses with immense commercial applications. We believe IPACKCHEM is a highly differentiated and sustainability-advantaged business with significant growth potential. We’ve been tremendously impressed by Jean-Philippe and the entire IPACKCHEM management team and we are excited to partner with them to execute our shared strategic objectives.”
Jean-Philippe Morvan, CEO of IPACKCHEM, noted, “We are delighted to partner with SK Capital as we embark on our next phase of growth. We believe their specialty chemicals expertise, functional and operating resources and extensive M&A capabilities will be instrumental in building on our existing strong market positions. Our common ambition is to accelerate organic and acquisitive growth and develop IPACKCHEM into the leading global barrier packaging player for Crop Protection and select Specialty Chemical markets.”
IPACKCHEM’s Board of Directors includes several highly experienced executives, including Rob Tiede, the former CEO of Sonoco Products, Dave Mezzanotte, SK Capital Senior Director and former Chairman and CEO of Coveris, and George Gregory, SK Capital Senior Director and former CEO of Kraton Polymers.
Rob Tiede, former CEO of Sonoco Products, commented, “IPACKCHEM is at the forefront of addressing many of today’s macroeconomic and socioeconomic issues. The Company’s highly specialized packaging products are of extremely high quality, enabling the safe handling and shipping of highly regulated Crop Protection chemicals that allow farmers to feed the world‘s growing population, and are 100% recyclable, helping to address environmental issues.”
Dave Mezzanotte, Senior Director at SK Capital, added, “IPACKCHEM is a global market leader with a technology differentiation that drives cost and sustainability benefits for customers. We see several actionable opportunities to further expand the Company’s addressable markets and to continue providing customers with high-quality and innovative products, as well as best-in-class service, globally.”
Acquisition financing was provided by Alcentra Ltd., Rothschild & Co served as M&A and financial advisor and Kirkland & Ellis acted as legal counsel to SK Capital.
About SK Capital
SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and pharmaceuticals sectors. The firm seeks to build strong and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $11 billion annually, employs more than 16,000 people globally and operates 146 plants in 28 countries. The firm currently has greater than $5 billion of assets under management. For more information, please visit www.skcapitalpartners.com .
About IPACKCHEM
Headquartered in Paris, France, IPACKCHEM is a leading global manufacturer of innovative plastic packaging products (containers, bottles, jerrycans) for the Crop Protection and Specialty Chemicals end markets. The Company’s UN-approved packaging solutions enable users to safely address the transportation and distribution of “hard-to-hold” and hazardous chemicals, while adhering to stringent regulations. IPACKCHEM operates globally through 8 production facilities, employs ~850 people and serves ~1,200 customers in 35 countries. For more information, please visit www.ipackchem.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005497/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom